University of Minnesota. Driven to Discover.
Peramivir, made by BioCryst, is intended to be given to influenza patients in a single intravenous dose.
The $275 million deal will make the company the second leading player in the $4 billion global flu vaccine market.
The multipronged attack includes an executive order, a national strategy, and a detailed PCAST report.
The bill provides increases for the CDC, DHS, and FDA and funds for pandemic readiness.
Get CIDRAP news and other free newsletters.
Sign up now»
Unrestricted financial support provided by
Grant support for ASP provided by Become an underwriter»
CIDRAP - Center for Infectious Disease Research and PolicyAcademic Health Center, University of Minnesota, Minneapolis, MN
© 2018 Regents of the University of Minnesota. All rights reserved.The University of Minnesota is an equal opportunity educator and employer.